CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 65 filers reported holding CUE BIOPHARMA INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,100,550 | -37.0% | 478,500 | 0.0% | 0.07% | -40.3% |
| Q2 2023 | $1,746,525 | +2.2% | 478,500 | 0.0% | 0.12% | -5.3% |
| Q1 2023 | $1,708,245 | +25.3% | 478,500 | 0.0% | 0.13% | -1.5% |
| Q4 2022 | $1,363,725 | +27.8% | 478,500 | 0.0% | 0.13% | +19.8% |
| Q3 2022 | $1,067,000 | -10.4% | 478,500 | 0.0% | 0.11% | -0.9% |
| Q2 2022 | $1,191,000 | -49.0% | 478,500 | 0.0% | 0.11% | -42.9% |
| Q1 2022 | $2,335,000 | -56.8% | 478,500 | 0.0% | 0.20% | -56.9% |
| Q4 2021 | $5,411,000 | -22.4% | 478,500 | 0.0% | 0.46% | -42.2% |
| Q3 2021 | $6,971,000 | +25.1% | 478,500 | 0.0% | 0.79% | +17.6% |
| Q2 2021 | $5,574,000 | -4.5% | 478,500 | 0.0% | 0.67% | -28.4% |
| Q1 2021 | $5,837,000 | -3.6% | 478,500 | -1.1% | 0.93% | -26.2% |
| Q4 2020 | $6,054,000 | -16.9% | 484,000 | 0.0% | 1.26% | -29.3% |
| Q3 2020 | $7,284,000 | – | 484,000 | – | 1.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 829,042 | $9,376,000 | 5.61% |
| P.A.W. CAPITAL CORP | 120,000 | $1,357,000 | 1.24% |
| Nantahala Capital Management | 2,539,700 | $28,724,000 | 1.01% |
| Slate Path Capital LP | 1,483,619 | $16,780,000 | 0.88% |
| SANDERS MORRIS HARRIS LLC | 359,113 | $4,416,000 | 0.76% |
| APOGEM CAPITAL LLC | 62,295 | $705,000 | 0.46% |
| Robertson Stephens Wealth Management, LLC | 478,500 | $5,411,000 | 0.46% |
| Bleichroeder LP | 200,000 | $2,262,000 | 0.35% |
| ADVISORY RESEARCH INC | 257,225 | $2,909,000 | 0.23% |
| Granite Point Capital Management, L.P. | 110,000 | $1,244,000 | 0.21% |